Table 5.
OR between the presence of replicon types and AMR or ESBL-producing E. coli (n = 1047) and Salmonella (n = 816)
| Bacterial strain | Type of replicons | OR of AMR phenotype (95% CI) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| AMP | CHP | CIP | GEN | STR | SMZ | TET | TMP | COL | ESBL producer | ||
| E. coli | HI1 | 4.96 (2.0–12.4)a | 2.62 (1.8–3.9)a | 5.46 (3.7–8.0)a | 5.0 (3.4–7.3)a | 3.7 (2.4–5.7)a | 4.2 (2.4–7.4)a | 12.1 (3.8–38.4)a | 2.56 (1.7–3.9)a | 6.83 (4.6–10.1)a | 2.5 (1.6–3.8)a |
| HI2 | na | na | na | – | na | na | na | – | 20.34 (6.7–62.1)a | 3.36 (1.3–8.7)a | |
| I1-γ | – | – | 0.52 (0.3–0.9)b | 4.77 (3.2–7.0)a | 2.5 (1.7–3.9)a | – | – | 0.55 (0.4–0.8)b | – | 6.33 (4.2–9.5)a | |
| N | 4.95 (1.8–13.7)a | 2.78 (1.8–4.3)a | 3.41 (2.3–5.1)a | 2.34 (1.6–3.5)a | 1.83 (1.2–2.8)a | 2.8 (1.6–4.7)a | 3.3 (1.6–6.9)a | 2.95 (1.8–4.8)a | 1.79 (1.1–2.8)a | 1.82 (1.1–2.9)a | |
| FIA | – | – | 3.67 (2.2–6.3)a | – | 2.0 (1.1–3.6)a | 5.22 (2.1–13.2)a | 2.61 (1.02–6.6)a | 2.53 (1.3–4.8)a | – | 0.19 (0.04–0.8)b | |
| FIB | 3.16 (1.9–5.3)a | 1.62 (1.2–2.1)a | 2.0 (1.5–2.7)a | – | 1.56 (1.2–2.1)a | 2.15 (1.6–3.0)a | 2.82 (1.8–4.3)a | 1.58 (1.2–2.1)a | 2.36 (1.7–3.3)a | – | |
| Y | 3.37 (1.5–7.4)a | – | 1.61 (1.1–2.4)a | 1.92 (1.3–2.8)a | 2.39 (1.6–3.6)a | – | 2.17 (1.2–3.9)a | 1.91 (1.3–2.9)a | 1.93 (1.3–3.0)a | 2.57 (1.7–4.0)a | |
| P | – | – | na | 0.1 (0.01–0.7)b | – | – | – | – | na | na | |
| FIC | – | 0.28 (0.1–0.6)b | – | – | – | – | – | – | – | – | |
| A/C | na | – | – | – | – | – | – | – | – | – | |
| FIIAs | – | – | – | 0.65 (0.4–0.9)b | – | – | – | – | 1.56 (1.02–2.3)a | 0.51 (0.2–0.9)b | |
| K | 2.38 (1.7–3.4)a | 2.39 (1.9–3.1)a | 1.77 (1.3–2.4)a | 1.99 (1.5–2.6)a | 2.2 (1.7–2.8)a | 2.38 (1.8–3.1)a | 3.3 (2.4–4.6)a | 2.07 (1.6–2.7)a | 1.47 (1.04–2.1)a | 2.0 (1.4–2.9)a | |
| B/O | – | – | – | – | – | – | na | 9.47 (1.3–72.0)a | 3.06 (1.1–8.5)a | na | |
| F | 2.17 (1.5–3.1)a | 1.87 (1.5–2.4)a | 1.4 (1.1–1.9)a | 2.55 (1.9–3.3)a | 1.57 (1.2–2.0)a | 1.59 (1.2–2.1)a | 3.0 (2.1–4.2)a | – | 2.76 (1.9–3.9)a | 3.23 (2.2–4.7)a | |
| Salmonella | HI1 | na | 46.8 (6.2–350.8)a | na | 4.04 (1.7–9.7)a | 0.22 (0.1–0.6)b | na | – | – | 11.9 (2.3–60.8)a | 159.9 (52.0–491.3)a |
| HI2 | – | – | na | – | – | na | – | – | na | na | |
| I1-γ | – | – | na | 4.5 (2.3–9.0)a | – | – | – | – | na | 5.8 (1.8–18.3)a | |
| N | – | 44.3 (5.9–332.7)a | 14.4 (4.7–43.9)a | 8.8 (3.3–23.2)a | – | – | – | – | na | na | |
| FIB | – | 4.8 (1.8–13.0)a | na | – | na | – | na | – | – | na | |
| Y | 0.17 (0.1–0.5)b | na | – | – | na | na | na | – | na | na | |
| FIC | 0.1 (0.02–0.7)b | – | na | na | – | – | 0.2 (0.04–0.98)b | – | 20.1 (2.1–191.6)a | na | |
| A/C | na | 14.8 (3.3–65.9)a | na | 14.96 (4.2–53.7)a | na | na | na | – | na | 24.5 (7.5–80.0)a | |
| FIIAs | 0.15 (0.1–0.2)b | – | – | – | 0.36 (0.2–0.6)b | – | 0.2 (0.1–0.3)b | – | – | – | |
| F | – | 4.85 (2.0–12.0)a | na | – | na | – | na | – | – | – | |
OR > 1, the resistance to the drug increased with the presence of corresponding replicon types.
OR < 1, the resistance to the drug decreased with the presence of corresponding replicon types.
a,bStatistically significant association (95% CI did not cross 1) between the presence of plasmids in particular Inc groups and resistant or ESBL-producing strains.
–, no statistically significant association (95% CI cross 1) between the presence of plasmids in particular Inc groups and resistant or ESBL-producing strains.
na, no OR due to the lack of the corresponding replicon types.
AMP, ampicillin; CHP, chloramphenicol; CIP, ciprofloxacin; GEN, gentamycin; STR, streptomycin; SMZ, sulphamethoxazole; TET, tetracycline; TMP, trimethoprim; COL, colistin.